Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-002744
Filing Date
2025-06-17
Accepted
2025-06-17 17:28:24
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11450
2 JOINT FILING AGREEMENT p25-1384exhibit99_1.htm EX-99.1 4846
  Complete submission text file 0000902664-25-002744.txt   17919
Mailing Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902
Business Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902 203-890-2000
Point72 Asset Management, L.P. (Filed by) CIK: 0001603466 (see all company filings)

EIN.: 465064661 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Subject) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92962 | Film No.: 251054423
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)